Page 5

Page One  Page Two  Page Three  Page Four  Page Five  Page Six  Page Seven  NAMA Advocate Index 

October 9, 2002 NIDA Contact: Michelle Person 301-443-6245 SAMHSA Contact: Leah Young 301-443-8956 Buprenorphine, a new medication developed through more than a decade of research supported by the National Institute on Drug Abuse (NIDA), will now become available to treat heroin and other opioid dependence through certification and training of physicians to use the medication…

Issues To Focus On LAAM Manufacture to Be Discontinued August 23, 2003 Washington, D.C. Roxanne the manufacturer of LAAM has informed the FDA that manufacture of the medication is being discontinued. Distribution will continue until the inventory is depleted. Roxanne estimates this to be in early January 2004. The reason for the action is the…

Sponsored by American Association for the Treatment of Opioid Dependence Washington, D.C. ~ April 13-16, 2003 Saturday, April 12, 2003 Pre-Conference Session A Day of Methadone Advocacy Training NAMA Moves Methadone Advocacy to a New Level with training and certification. Includes a Photo Album of the Day and Jo L. Sotheran’s presentation on Working a…

Page One  Page Two  Page Three  Page Four  Page Five  Page Six  Page Seven  NAMA Advocate Index 

Education Series Number 10 June 2004 The New Federal Regulations What Do They Mean for Patients? Methadone treatment in the U.S. is changing before our eyes. Some of this change has been rapid; some of it will take years or decades. Some patients have heard about new federal regulations, including an end to automatic dose…